MIAMI--(BUSINESS WIRE)--July 15, 2005--IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX), received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for hydrochlorothiazide capsules 12.5 mg. This product will be sold through IVAX’ wholly owned subsidiary, IVAX Pharmaceuticals, Inc. Hydrochlorothiazide capsules 12.5 mg is the generic equivalent of Microzide(TM) Capsules 12.5 mg which is marketed by Watson Pharmaceuticals, Inc. and is indicated for the management of hypertension. According to IMS data, annual U.S. sales of Microzide Capsules 12.5 mg and hydrochlorothiazide capsules 12.5 mg were $41.7 million for the 12 months ended March 31, 2005.
